Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSK | P43235 | 4/20 | 0.40 |
| ▸ | CAPN1 | P07384 | 7/20 | 0.39 |
| ▸ | CASP3 | P42574 | 4/20 | 0.38 |
| ▸ | CASP1 | P29466 | 2/20 | 0.38 |
| ▸ | CASP7 | P55210 | 1/20 | 0.38 |
| ▸ | CASP6 | P55212 | 1/20 | 0.38 |
| ▸ | CASP8 | Q14790 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.38 |
| ▸ | MMP1 | P03956 | 1/20 | 0.37 |
| ▸ | GAA | P10253 | 1/20 | 0.36 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.36 |
| ▸ | CCNA2 | P20248 | 1/20 | 0.35 |
| ▸ | CDK2 | P24941 | 1/20 | 0.35 |
| ▸ | CCNA1 | P78396 | 1/20 | 0.35 |
| ▸ | PSEN1 | P49768 | 1/20 | 0.35 |
| ▸ | PSEN2 | P49810 | 1/20 | 0.35 |
| ▸ | APH1B | Q8WW43 | 1/20 | 0.35 |
| ▸ | NCSTN | Q92542 | 1/20 | 0.35 |
| ▸ | APH1A | Q96BI3 | 1/20 | 0.35 |
| ▸ | PSENEN | Q9NZ42 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3956512 | 1.00 | CTSK (0.40) | CTSKCAPN1CASP3CASP1CASP7 | |
| SCHEMBL4310643 | 0.84 | CTSK (0.47) | CTSKCAPN1SMN1; SMN2GAA | |
| SCHEMBL4310652 | 0.84 | CTSK (0.47) | CTSKCAPN1SMN1; SMN2GAA | |
| SCHEMBL4310638 | 0.84 | CTSK (0.47) | CTSKCAPN1SMN1; SMN2GAA | |
| SCHEMBL13784692 | 0.84 | CTSK (0.47) | CTSKCAPN1SMN1; SMN2GAA | |
| SCHEMBL4310648 | 0.84 | CTSK (0.47) | CTSKCAPN1SMN1; SMN2GAA | |
| SCHEMBL5099466 | 0.84 | CTSK (0.47) | CTSKCAPN1SMN1; SMN2GAA | |
| SCHEMBL4769110 | 0.81 | CPB2 (0.42) | CTSK | |
| SCHEMBL4769153 | 0.81 | CAPN1 (0.39) | CTSKCAPN1CASP3CASP1CASP7 | |
| SCHEMBL6211927 | 0.81 | CTSK (0.39) | CTSKCAPN1CASP3CASP1CASP7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 73 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1796677-A4 | METHOD FOR ACTIVATING TRPV4 CHANNEL RECEPTORS BY AGONISTS | SMITHKLINE BEECHAM CORP (US) | 2009-07-08 | — | — | EP | disclosed |
| EP-1320370-A4 | METHOD OF TREATMENT | SMITHKLINE BEECHAM CORP (US) | 2008-10-22 | — | — | EP | disclosed |
| EP-1384713-B1 | 4-amino-azepan-3-one derivatives as protease inhibitors | SMITHKLINE BEECHAM CORP (US) | 2008-10-15 | — | — | EP | disclosed |
| US-7405209-B2 | e.g. 2-Benzyloxycarbonylamino-4-methyl-pentanoyl)-3-oxo-azepan-4-ylcarbamoyl}carbamic acid benzyl ester; protease inhibitors like cathepsin K; osteoporosis, osteo- and rheumatoid arthritis and periodontal disease; inhibiting excessive cartilage or matrix degradation | SMITHKLINE BEECHAM CORPORATION (US) | 2008-07-29 | — | — | US | disclosed |
| US-20070259856-A1 | Method for Activating Trpv4 Channel Receptors by Agonists | SMITHKLINE BEECHAM CORPORATION | 2007-11-08 | — | — | US | disclosed |
| EP-1796677-A2 | METHOD FOR ACTIVATING TRPV4 CHANNEL RECEPTORS BY AGONISTS | SMITHKLINE BEECHAM CORPORATION (US) | 2007-06-20 | — | — | EP | disclosed |
| WO-2006029209-A2 | METHOD FOR ACTIVATING TRPV4 CHANNEL RECEPTORS BY AGONISTS | SMITHKLINE BEECHAM CORPORATION (US) | 2006-03-16 | — | — | WO | disclosed |
| EP-1303281-A4 | METHODS OF TREATMENT | SMITHKLINE BEECHAM CORP (US) | 2006-02-15 | — | — | EP | disclosed |
| US-20050256104-A1 | substituted 1,1,4-1l6-trioxo[1,2]thiazepan-4-ylamide-derived protease inhibitors which inhibit the likes of cathepsin K; treating osteoporosis, osteo- and rheumatoid arthritis and periodontal disease; inhibiting excessive cartilage or matrix degradation | SMITHKLINE BEECHAM CORPORATION | 2005-11-17 | — | — | US | disclosed |
| US-20040229863-A1 | Protease inhibitors | SMITHKLINE BEECHAM CORPORATION | 2004-11-18 | — | — | US | disclosed |
| WO-2001034159-A1 | PROTEASE INHIBITORS | SMITHKLINE BEECHAM CORPORATION (US) | 2001-05-17 | — | — | WO | disclosed |
| WO-2001034160-A1 | PROTEASE INHIBITORS | SMITHKLINE BEECHAM CORPORATION (US) | 2001-05-17 | — | — | WO | disclosed |
| WO-2001034565-A2 | PROTEASE INHIBITORS | SMITHKLINE BEECHAM CORPORATION (US) | 2001-05-17 | — | — | WO | disclosed |
| WO-2001034566-A2 | PROTEASE INHIBITORS | SMITHKLINE BEECHAM CORPORATION (US) | 2001-05-17 | — | — | WO | disclosed |
| WO-2001034600-A1 | PROTEASE INHIBITORS | SMITHKLINE BEECHAM CORPORATION (US) | 2001-05-17 | — | — | WO | disclosed |
| WO-2001034158-A1 | PROTEASE INHIBITORS | SMITHKLINE BEECHAM CORPORATION (US) | 2001-05-17 | — | — | WO | disclosed |
| WO-2001034155-A1 | PROTEASE INHIBITORS | SMITHKLINE BEECHAM CORPORATION (US) | 2001-05-17 | — | — | WO | disclosed |
| WO-2001034154-A1 | PROTEASE INHIBITORS | SMITHKLINE BEECHAM CORPORATION (US) | 2001-05-17 | — | — | WO | disclosed |
| WO-2001034157-A1 | PROTEASE INHIBITORS | SMITHKLINE BEECHAM CORPORATION (US) | 2001-05-17 | — | — | WO | disclosed |
| WO-2000038687-A1 | PROTEASE INHIBITORS | SMITHKLINE BEECHAM CORPORATION (US) | 2000-07-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070259856-A1 | Method for Activating Trpv4 Channel Receptors by Agonists | TRPV4, TRPV2, TRPV3 | CTSK 410/4885CAPN1 408/4885CASP3 1131/4885 |
| US-20050256104-A1 | substituted 1,1,4-1l6-trioxo[1,2]thiazepan-4-ylamide-derived protease inhibitors which inhibit the likes of cathepsin K; treating osteoporosis, osteo- and rheumatoid arthritis and periodontal disease; inhibiting excessive cartilage or matrix degradation | CTSK, CTSZ, CTSE | CTSK 1/4885CAPN1 86/4885CASP3 461/4885 |
| US-20040229863-A1 | Protease inhibitors | CTSS, CTSE, CTSF | CTSK 6/4885CAPN1 249/4885CASP3 228/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.